Roland Wandeler, a former executive at Amgen Inc, has been appointed chief commercial officer at MorphoSys AG whose lead cancer product is under priority review at the US Food and Drug Administration. Assuming regulatory approval is forthcoming, Dr Wandeler will manage the product’s launch in the US as well as lead MorphoSys’ commercial operations worldwide. At Amgen, he was general manager of bone health and cardiology in the US, following earlier commercial roles in Germany, Spain and Portugal.
Dr Wandeler began his career at the Boston Consulting Group. He holds a MSc in chemical engineering and a doctorate in technical sciences from ETH Zurich, Switzerland.
MorphoSys announced the appointment on 22 April 2020.
Copyright 2020 Evernow Publishing Ltd.